Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
98
resultados
Última actualización
03/05/2025 [07:23:00]
Resultados 25 a 50 de 98
Resumen de: WO2025063348A1
The present invention relates to a novel bacteriophage having specific killing ability against Salmonella enterica and an antibacterial composition comprising same, wherein the composition comprising the bacteriophage as an active ingredient can be usefully employed as a composition for preventing or treating infectious diseases caused by Salmonella enterica, feed for livestock, drinking water, a cleaning agent, and a disinfectant.
Resumen de: US2025099564A1
A vaccine for treating Salmonella enteriditis that includes an immunogenically effective amount of a Salmonella enteritidis protein InvG, and optionally a pharmaceutically acceptable carrier is described. Methods of using compositions that include the Salmonella Enteritidis protein InvG or a delivery vector that expresses Salmonella Enteritidis protein InvG for immunizing poultry against Salmonella Enteritidis are also described.
Resumen de: AU2023361317A1
The present invention relates to a modified live attenuated Gram-negative bacteria, wherein said bacteria has been modified in such a way that RNA molecules can be safely and efficiently delivered to target eukaryotic cells. As such, the present invention relates a to a bacterial delivery system and various uses and methods thereof.
Resumen de: KR20250041982A
본 발명은 비장티푸스성 살모넬라 2가 백신의 면역원성 동시 측정용 혈청사멸분석법에 관한 것이다.
Resumen de: WO2023223331A1
The present invention relates to diagnostic platform. More specifically, the invention relates to a dual platform composed of a detection and quantification unit and a characterization unit, systems, kits, methods and uses thereof in detection, quantification and characterization of pathogens, the system comprising monoclonal-antibody-based biosensor chips, for detection and/or quantification of pathogens in a sample, and substrate-based biosensor chips for enzymatically profiling the pathogen in the sample.
Resumen de: AU2023338191A1
The present invention provides compositions and methods for inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live
Resumen de: AU2022480516A1
Provided is a method against Salmonella typhimurium infection using a composition containing cultures of Lactobacillus rhamnosus LRH10 which is deposited at the Deutsche Sammlung Von Mikroorganismen und Zellkulturen (DSMZ) GmbH under an accession number DSM 32786, Lactobacillus paracasei LPC12 which is deposited at the DSMZ GmbH under an accession number DSM 32785, Lactobacillus fermentum LF26 which is deposited at the DSMZ GmbH under an accession number DSM 32784，Streptococcus thermophilus ST30 which is deposited at the DSMZ GmbH under an accession number DSM 32788, and Lactobacillus helveticus LH43 which is deposited at the DSMZ GmbH under an accession number DSM 32787.
Resumen de: US2025093348A1
A nucleic acid testing device and method are provided. A base plate that is turned during nucleic acid testing is included, wherein the base plate includes the following chambers: a sample chamber for adding and containing a nucleic acid sample solution, the nucleic acid sample solution is placed in the chamber, and an upper port of the sample chamber communicates with the outside atmosphere; a reaction chamber for nucleic acid amplification reaction and located below the sample chamber, a nucleic acid amplification reagent for nucleic acid amplification reaction is pre-placed in the chamber, and an upper end of the reaction chamber communicates with a bottom end of the sample chamber though a longitudinal liquid channel; a test strip chamber for lateral flow test strip testing, a nucleic acid test strip is pre-placed in the chamber, and the test strip chamber communicates with the reaction chamber through a bent channel.
Resumen de: US2025092355A1
The invention relates to compositions and methods, including polynucleotide sequences, amino acid sequences, and engineered host cells for producing fatty acids and derivates of fatty acids such as acyl-CoA, terminal olefins, fatty aldehydes, fatty alcohols, alkanes, alkenes, wax esters, ketones and internal olefins through altered expression of the transcription factor, fadR.
Resumen de: CN119633101A
本发明公开了SseB蛋白在制备交叉免疫同源或异源血清型肠炎沙门菌的疫苗中的应用。本发明使用动物实验评估其免疫保护力，结果发现肠炎沙门菌SseB蛋白具有良好的免疫反应性，可以显著减轻肠炎沙门菌同源或异源血清型野生菌株引起的临床症状。本发明涉及的具有交叉免疫保护作用的肠炎沙门菌SseB蛋白，具有作为研制肠炎沙门菌亚单位疫苗的潜力。
Resumen de: US2025082751A1
The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.
Resumen de: WO2025054360A1
The disclosure provides for a vaccine depot formulation that comprises a biodegradable thermosensitive hydrogel that has been loaded or embedded with nanoparticles that comprise an antigen and adjuvant, and uses thereof for protecting a subject from an infection or disease.
Resumen de: US2025084490A1
The invention refers to a method for simultaneous detection and quantification of Listeria monocytogenes, Salmonella spp. and Shiga toxin-producing Escherichia coli (STEC), from any kind of sample related to food production, including complex food matrices such as fish, meat, or fruit; or simple matrices such as water, or food contact surfaces. The method of invention allows specific quantification of the above-mentioned pathogens simultaneously thanks to specificity of designed primers for the qPCR reaction. It is also highly reliable because the method includes a system to adequately control the quantification of pathogens within the matrix. This system comprises the inoculation of samples with a known concentration of a transformed microorganism (host) carrying a chimeric sequence, acting as an internal control host for the whole process.
Resumen de: AU2023312737A1
Provided herein are vaccine composition comprising a
Resumen de: KR20250031183A
본 발명은 표적단백질을 효율적으로 분비할 수 있는 살모넬라 균주 및 이의 제조방법에 관한 것으로, fliD 유전자가 불활성화되어, 플라젤린 단백질의 분비가 증가된 변이 살모넬라 균주를, 표적 단백질과 flgM 단백질의 융합단백질을 암호화하는 유전자를 포함하는 유전자 구조물로 형질전환하여, 표적 단백질과 flgM 단백질의 융합단백질 형태로 표적단백질을 분비하는 것을 특징으로 하는 살모넬라 균주 및 이의 제조방법에 관한 것이다.
Resumen de: US2025074952A1
Provided is a structure for capturing a compound that includes at least one gene or a product thereof, or a combination thereof among a group of genes involved in the intracellular and extracellular transport function of the compound, the gene or the product thereof being multi-componented.
Resumen de: US2025073282A1
The present invention relates to the technical field of probiotics, in particular to a Lactiplantibacillus plantarum GOLDGUT-LP618 having a function of resisting Salmonella infection and application thereof. The Lactiplantibacillus plantarum GOLDGUT-LP618 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28399. The strain has high resistance to acid and bile salt and can adapt to the digestive tract environment. The strain can inhibit Salmonella infection, relieve diarrhea, inflammation and intestinal damage caused by Salmonella infection, and promote intestinal health. The strain can be used for preparing functional foods, dietary supplements or drugs that can resist Salmonella infection and improve diarrhea and inflammation caused by Salmonella infection, and has good application prospects.
Resumen de: US2025073163A1
The present invention provides a method of treating an infectious disease. The method comprises the step of administering to a subject in need thereof an effective amount of (i) a polymer-flavonoid conjugate, (ii) a flavonoid oligomer, or (iii) micelles having a shell formed by one or more polymer-flavonoid conjugates or one or more flavonoid oligomers, or the combination thereof, and having an agent encapsulated within the shell. The present method is effective to treat viral infection, e.g., severe acute respiratory syndrome coronavirus (SARS-CoV), enterovirus virus, HIV, hepatitis B virus, MERS-CoV, influenza virus, Dengue virus, respiratory syncytial virus, hepatitis C virus, monkeypox virus, human papillomavirus, methicillin-resistant Staphylococcus aureus, Pseudomonas, tuberculosis, Bacillus anthracis, Tetani bacterium, Streptococcus pneumoniae, meningococcus, Escherichia coli, Legionella, Neisseria gonorrhea, Neisseria meningitidis, and Salmonella.
Resumen de: AU2023262222A1
The invention relates to a gelled reaction medium for the detection, identification, enumeration and/or isolation of at least one target microorganism in a sample that may contain same, comprising at least one binding partner specific to a component of a target microorganism or of a component derived from said microorganism, coupled to at least one nanoparticle to form at least one binding conjugate.
Resumen de: KR20250030119A
본 발명은 신규한 살모넬라 엔테리티디스 온도감수성 변이주에 관한 것으로, 본 발명의 변이 균주는 야생형 균주가 번식하는 닭의 정상 체온인 40 내지 45 ℃에서 성장이 억제되어 집락 형성을 억제하므로, 면역화된 무리 내에서 백신 균주가 장기 순환함으로써 치명적인 복귀 돌연변이체가 될 수 있는 위험성이 없는 충분히 약화된 비병원성 백신 균주이며, 닭에서 살모넬라 엔테리티디스에 대항하여 충분한 안전성, 방어 효능 및 면역 반응을 나타냈고, 그에 일치한 표현형 및 유전형 변화도 보였으므로, 이를 온도감수성(온도민감성) 약독화 생균 백신의 유효성분으로 유용하게 사용할 수 있다.
Resumen de: JP2023175686A
To provide compositions for use in enhancing human immune response and/or as adjuvants in vaccines.SOLUTION: A composition includes an antigen and a specific imidazopyrimidine compound.SELECTED DRAWING: None
Resumen de: CN119523975A
The invention belongs to the technical field of biological medicines, and discloses application of indometacin combined with polymyxin in resisting salmonella infection. A checkerboard method minimum inhibition concentration test and an in-vitro time-sterilization curve test prove that the indometacin and colistin combined drug has an obvious synergistic effect on salmonella resistance, and the indometacin can enhance the antibacterial effect of the colistin drugs on salmonella standard strains and colistin-resistant salmonella. The invention provides a new drug combination strategy, and provides a new research thought and research and development direction for solving the increasingly serious drug resistance problem of polymyxin.
Resumen de: CN119530114A
The invention relates to a method for constructing strict anaerobic salmonella, the strict anaerobic salmonella constructed by using the method and application of the strict anaerobic salmonella in tumor treatment.
Resumen de: CN119530098A
The invention discloses a lactobacillus bornicaule NM3 and application thereof, and belongs to the field of microorganisms. The lactobacillus pocortisone NM3 is preserved in the Guangdong Microbiological Culture Collection Center, and the preservation number is GDMCC NO: 65604. The strain is screened from intestinal tracts of spotted-brown chickens, is good in source safety, has a good inhibition effect on pathogenic bacteria including salmonella pullorum, escherichia coli and the like, has good application potential in the aspect of preventing and treating the pathogenic bacteria, is wide in prospect, can be used for preparing products for preventing and treating the pathogenic bacteria, and has wide application prospects. The strain is a probiotic strain worthy of development.
Nº publicación: CN119530363A 28/02/2025
Solicitante:
牛津纳米孔科技公开有限公司
Resumen de: JP2024012307A
To provide modified or mutant forms of secretin and compositions comprising the same, and methods for using modified or mutant forms of secretin and compositions for characterizing an analyte, e.g., a target polynucleotide.SOLUTION: The disclosure provides analyte detection using a modified secretin as a nanopore. The disclosure provides a modified secretin nanopore disposed in a membrane, wherein the modified secretin nanopore comprises a lumenal surface defining a lumen that extends through the membrane between a cis-opening and a trans-opening, wherein the lumenal surface comprises one or more amino acid modifications.SELECTED DRAWING: None
BOPI
Sede Electrónica
